SYDNEY, AUSTRALIA--(Marketwired - Jun 19, 2014) - Prima BioMed Ltd (
Dr. Heidi Gray, lead investigator, will deliver a presentation on final progression free survival (PFS) and interim overall survival (OS) data for Epithelial Ovarian Cancer patients in First or Second Remission (the CAN-003 protocol). As outlined in her presentation to the American Society of Clinical Oncology (ASCO) Annual Meeting on 31 May and as previously announced, Dr Gray will highlight the positive trends demonstrated in PFS and OS for CVac in the second remission patient population.
The following are specific details regarding Prima's presentation. Event: 2014 WAGO Annual Meeting Date: Thursday, June 26, 2014 Time: 10:35am - 10:45am Location: Ritz Carlton Lake Tahoe, Salon III
About Prima BioMed Prima BioMed is a globally active leader in the development of personalized immunocellular therapeutic products for the treatment of cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials. www.primabiomed.com.au
For further information please contact: USA Investor/Media: Adam Holdsworth ProActive Capital +1 (646) 862 4607 Email Contact Australia Investor/Media: Mr Matthew Gregorowski Citadel Communications +61 (0) 422 534 755 Email Contact Europe Investor/Media: Mr. Axel Muhlhaus edicto GmbH +49 (0) 69 905505-52 Email Contact